FDA approves dabrafenib plus trametinib for BRAF V600E low-grade glioma in childrenNov 10Regulatory decisiondabrafenibNovartis
Novartis registers new Phase 2 NIO752 tauopathy trial; Egaten results, six studies updateOct 9Weekly roundup, 8 itemsinclisiraniptacopanUpdated
Novartis-linked melanoma trial posts results; new ITP preference survey and LASIK study activeAug 27Weekly roundup, 4 itemsdabrafenibitraconazole
Novartis updates Leqvio label; MS study recruiting, thyroid study not yet recruitingAug 21Weekly roundup, 8 itemsGIA632inclisiran